Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes

International Journal of Clinical Practice

Volumn 55, Issue 3, 2001, Pages 177-182

  Roach, P ^a,c   Strack, T ^a,b   Arora, V ^a,b   Zhao, Z ^a,b   Lilly, Eli ^a,b  

^a Abbott Laboratories ^*

^b ABBOTT LABORATORIES   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ANTIBODY; INSULIN LISPRO; INSULIN[B28 LYSINE B29 PROLINE]PROTAMINE; ISOPHANE INSULIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG FORMULATION; DRUG MIXTURE; DRUG SYNTHESIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN ALLERGY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEAL; MEASUREMENT; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PRURITUS; RANDOMIZATION; RASH; RISK; SUSPENSION; TIME; URTICARIA;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ANTIBODIES; MALE; MIDDLE AGED; PROTAMINES;

EID: 0035027653     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Koivisto VA. The human insulin analogue insulin lispro. Ann Med 1998; 30: 260-266.
2. Anderson JH Jr. Brunelle RL, Koivisto VA et ni. Reduction of postprandial hyperglycemia and frequency of hypoglyccmia in IDDM patients on insulin-analog treatment. Diabetes 1997: 46: 265-270.
3. Anderson JH Jr. Brunelle RL, Keohane P el ul. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Mcd 1997;157: 1249-1255.
4. Fineberg NS. Fineberg SE. Anderson JH et al. Immunologie effects of insulin lispro [Lys (B28), Pro (B29) human insulin) in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996: 45: 1750-1754.
5. IMS. Health, 1997. Data on file, Eli Lilly and Company.
6. WHO Classification of Diabetes. In: Pickup JC. Williams G. Eds. Textbook of diabetes, vol 1, Oxford: Blackwell Scientific Publications, 1991: 39.
7. Ottesen JL, Nilsson P. Weilguny D cl al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 1994; 37: 1178-1185.
8. Huang J, Brunelle R, Fineberg E, Anderson JH. Long term monitoring of insulin antibody responses in patients treated with insulin lispro (Humalog). Diabetes 1999; 48(suppl 1): A94-A95.
9. Heise T. Weyer C, Servvas A el til. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Cure 1998: 21: 800-803.
10. Vignati L, Anderson JH Jr. Iversen PW. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulindependent or non-insulin-dependenl diabetes mellitus. Clin Tlier 1997; 19: 1408-1421.
11. Roach P. Yue L. Arora V. Improved postprandial glycemie control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999; 22: 1258-1261.
12. Roach P. Trautmann M. Arora V et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50. Clin Ther 1999; 21: 523-534.
13. Fineberg SE. Anderson JH Jr. Complications of insulin therapy. In: Alberti KOMM. Zimmet P, DeFronJ.o RA, Eds. International textbook of diabetes mellitus, 2nd edn. London: Wiley, 1996; 955-963.